Table 1.
Results from all combination treatment studies.
| Time to >5% Weight Loss | Overall Weight Loss | Clinical Score | Survival | |
|---|---|---|---|---|
| Study 1 (n=5 or 6) | ||||
| Combo vs. PBS | P=0.049 | P=0.003 | P=0.003 | P=0.0005 |
| Combo vs. VIG | P=0.82 | P=0.06 | P=0.006 | P=0.005 |
| Study 2 (n=5) | ||||
| Combo vs. control mAb | P=0.02 | P=0.017 | P<0.0001 | P=0.003 |
| Combo vs. VIG | P=0.15 | P=0.98 | P=0.01 | P=0.49 |
| Study 3 (n=10) | ||||
| Combo vs. control mAb | P=0.0009 | P=0.0006 | P<0.0001 | P<0.0001 |
| Combo vs. VIG | P=0.07 | P=0.04 | P=0.06 | P=0.03 |
| Combo vs. C12 | P=0.34 | P=0.16 | P=0.42 | P=0.22 |
| Combo vs. D67 | P=0.19 | P=0.051 | P=0.16 | P=0.036 |
| Study 4 (n=10) | ||||
| Combo vs. control mAb | P<0.0001 | P<0.0001 | P<0.0001 | P=0.0015 |
| Combo vs. VIG | P=0.0009 | P=0.039 | P=0.0036 | P=0.14 |
| Combo vs. C12 | P=0.084 | P=0.40 | P=0.03 | P=0.37 |
| Meta-Analysis | ||||
| Combo vs. control mAb | P<0.0001 | P<0.0001 | P<0.0001 | P<0.0001 |
| Combo vs. VIG | P=0.0002 | P=0.0004 | P=0.0006 | P=0.0003 |
| Combo vs. C12 | P=0.046 | P=0.049 | P=0.096 | P=0.006 |